Clinical research studies are vital to the process of discovering the safest and most effective cancer therapies for patients. The C.R. Wood Cancer Center currently has approximately 40 national clinical studies available for treatment, quality of life and prevention of different cancers. Glens Falls Hospital has partnered with the University of Vermont for shared opportunities in their clinical studies, and the center also participates in clinical studies directly through pharmaceutical companies. The physicians and staff of the C.R. Wood Cancer Center work closely with these well respected organizations, along with the National Cancer Institute, to provide opportunities for local patients to take part in national clinical research studies, without having to travel away from home. These studies provide the opportunity for patients to conveniently receive some of the most cutting edge therapies available, while also allowing them to directly contribute to the ongoing progress being made in the field of oncology. Treatment studies may consist of chemotherapy, immunotherapy, radiation therapy, hormonal therapy or combination therapy. Learn more about clinical trials by visiting clinicaltrials.gov
For more information on clinical studies, contact Beth Ann Brundage, RN, OCN, at 518-926-6644 or Nannette Oberhelman, at 518-926-6701.
Clinical Trials
ANOREXIA
CTSU A222004
A Randomized Phase III Trial of Olanzapine Versus Megestrol Acetate for Cancer-Associated Anorexia
BLADDER
An Integrated Phase 2/3 and Phase 3 Trial of MRD-Based Optimization of Adjuvant Therapy in Urothelial Cancer (MODERN)
BREAST
CTSU A011801
he CompassHER2 trials (COMprehensive use of Pathologic Response Assessment to optimize therapy in HER2-positive breast cancer): CompassHER2 Residual Disease (RD), a double-blinded, phase III randomized trial of T-DM1 and placebo compared with T-DM1 and tucatinib”
A Phase III Clinical Trial Evaluating DE-escalation of Breast RAdiation (DEBRA) for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
P Registry
Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer. (Also under Registries)
OptimICE-PCR: DeEscalation of Therapy in Early Stage TNBC Patients Who Achieve pCR After Neoadjuvant Chemotherapy with Checkpoint Inhibitor Therapy
A Phase III Adjuvant Trial Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients with pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score
Phase III Trial of Neoadjuvant Durvalumab Plus Chemotherapy vs. Chemotherapy Alone for Adults with MammaPrint Ultrahigh (MP2) Hormone Receptor (HR) Positive/Human Epidermal Growth Factor Receptor (HER2) Negative Stage II-III Breast Cancer
A Phase III Randomized Trial, Shorter Anthracycline-Free Chemo/Immuno-therapy Adapted to Pathological Response in Early Triple Negative Breast Cancer
Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer Survivors: A Multi-Center Randomized Double-Blinded Controlled Trial
COLON/RECTAL
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease (CIRCULATE-US)
Randomized Trial of Consolidation Targeted Adjuvant Therapy with Encorafenib and Cetuximab versus Usual Care for Patients with Stage II/III BRAF V600E Colon Cancer
GASTRIC/ESOPHAGEAL
Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab Versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS >/= 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
LEUKEMIA
CTSU S1925
Randomized, Phase III Study of Early Intervention with Venetoclax and Obinutuzumab vs. DeLayed Therapy with VEnetoclax and Obinutuzumab in Newly Diagnosed Asymptomatic High-Risk Patients with Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): EVOLVE CLL/SLL Study
LUNG
NSCLC Limited
CTSU EA5181
Randomized Phase III Trial of MEDI4736 (durvalumab) as Concurrent and Consolidative Therapy or Consolidative Therapy Alone for Unresectable Stage 3 NSCLC
LYMPHOMA
A Randomized Phase 3 Interim Response Adapted Trial Comparing Standard Therapy with Immuno-oncology Therapy for Children and Adults with Newly Diagnosed Stage I and II Classic Hodgkin Lymphoma
NSCLC Advanced
CTSU EA5182
Randomized Phase 3 Study of Combination AZD9291 (osimertinib) and Bevacizumab versus AZD9291 (osimertinib) Alone as First-Line Treatment for Patients with Metastatic EGFR-Mutant Lung Cancer
CTSU NRG-LU008
Phase III Prospective Randomized Trial of Primary Lung Tumor Stereotactic Body Radiation Therapy Followed by Concurrent Mediastinal Chemoradiation for Locally Advanced Non-Small Cell Lung Cancer
Randomized Phase 3 Clinical Trial of Chemo-Immunotherapy vs Immunotherapy Alone for the Vulnerable Older Adult with Advanced Non-Small Cell Lung Cancer: The ACHIEVE Study (ONLY PS 2)
OTHER
PANCREATIC
A Randomized Phase II Study of Gemcitabine and Nab-Paclitaxel Compared with 5-Fluorouracil, Leucovorin, and Liposomal Irinotecan in Older Patients with Treatment Naïve Metastatic Pancreatic Cancer (GIANT)
Phase II/III Second-Line NABPLAGEM vs. Nab-Paclitaxel/Gemcitabine in BRCA1/2 or PALB2 Mutant Metastatic Pancreatic Ductal Adenocarcinoma (PLATINUM
PROSTATE
CTSU S1802
Phase III Randomized Trial of Standard Systemic Therapy (SST) vs. Standard Systemic Therapy Plus Definitive Treatment (Surgery or RT) of the Primary Tumor in Met. Prostate Cancer
REGISTRIES
P Registry
Breast Cancer Collaborative Registry (BCCR) for patients who have breast cancer that has been recently diagnosed, have a history of breast cancer, or are at high risk of developing breast cancer, or because relatives have been diagnosed with breast cancer.
NOTE: Other studies are available to us through the University of VT; we open them as Research Nurse identifies an eligible patient.